The SOFA score—development, utility and challenges of accurate assessment in clinical trialsSimon Lambden, Bruno François, Mitchell M. Levy et al.|Critical Care|2019Cited by 976
Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trialBruno François, Thorbjørn Grøfte, Mitchell M. Levy et al.|The Lancet Respiratory Medicine|2023Cited by 76
Rationale and protocol for the efficacy, safety and tolerability of nangibotide in patients with septic shock (ASTONISH) phase IIb randomised controlled trialBruno François, Pierre‐François Laterre, Valérie Cuvier et al.|BMJ Open|2021Cited by 20
Evaluation of the efficacy and safety of TREM-1 inhibition with nangibotide in patients with COVID-19 receiving respiratory support: the ESSENTIAL randomised, double-blind trialBruno François, Sébastien Gibot, Mitchell M. Levy et al.|EClinicalMedicine|2023Cited by 18